Vincent, they are simply cooperating, and certainly have access to the same information, according to the F.Post March 22 issue, where analysts are 'analyzed'. (Excuse me if this sounds pompous, or like I have some insight or wisdom denied to the masses. I feel very ignorant and confused most of the time.)
It is slanderous to say they are colluding, in any event. All we can do is quote them, and hope that this will in turn sway other investors to think the way we do, to our profit.
A recent Globe issue (Monday March 24) quoted Lwowski, a Yorkton analyst, as saying Draxis, Microbioloix, and Synsorb would rise.
Marleau Lemire analyst L.Gibbs was also quoted as bullish on biotechs. Which reminds me that the Montreal Gazette on March 10 published an article that indicated that the Ont.Securities Commission was investigating serious accusations of improper advice from broker R.Groome of Marleau Lemire, regarding a speculative stock. There is always dirt to dig; some brokerages (First Marathon Calgary for example) have earned a very bad name.
Conclusion: analysts' advice can be very treacherous.
--------------------------------------
News Posting: I see this (Cd.) as very promising. I am happy to have bought Syb recently at 10.75. 10.10, and 9.60. (Especially after buying in at 2.80 and selling early.) I would buy more, under $10, but after all, this is a speculative stock, however wonderful I think it is.
I hope (with no justification) for a double in 6-12 months.
--------------------------------------------
Phase II clinical trial for Synsorb Cd to begin in May
Synsorb Biotech Inc SYB
Shares issued 16,084,520 Mar 24 close $9.45
Tue 25 Mar 97 News Release
Mr Brad Thompson reports
Synsorb Biotech has launched a phase II clinical trial scheduled to start
at the beginning of May 1997, for Synsorb Cd, a potential treatment for
recurring episodes of C. difficile associated diarrhea.
This announcement follows the successful completion of a phase I safety
study which demonstrated Synsorb Cd was safe and well tolerated by healthy
adults over a three week treatment period.
The phase II clinical trial, a double blind, placebo controlled dose range
trial will enroll patients with recurrent C. difficile infection at 18
centres across Canada.
C. difficile associated diarrhea (CDAD) is one of the most common hospital
borne infections and is a growing threat to hospitalized patients in North
America and Europe. Up to 8.75 million North Americans, Western Europeans
and Japanese contract the infection each year, usually as a result of
antibiotic therapy administered to treat other conditions.
Symptoms of the infection include severe diarrhea, cramping, abdominal pain
and fever which, in the majority of cases, can be treated with other
antibiotics. However, up to 1.75 million patients in the First World each
year do not respond to this therapy. These individuals develop a recurring
form of the condition which can lead to serious complications, including
pseudomembranous colitis, ulceration of the colon and sometimes death.
Synsorb Cd is designed to treat recurring C. difficile infections and is
the company's second product under clinical investigation.
(c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com |
